| Trial ID: | L0339 |
| Source ID: | NCT02672293
|
| Associated Drug: |
Phoslax
|
| Title: |
Determining Oral Phosphate Tolerance Across the Spectrum of Glomerular Filtration Rate
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: Phoslax
|
| Outcome Measures: |
Primary: Fractional excretion of phosphate, Fractional excretion of phosphate will be measured at baseline and at 1 and 2 hours following a standardized oral phosphate challenge, Change in fractional excretion of phosphate at 1 and 2 hours | Secondary: Fibroblast growth factor-23, Biomarker of phosphate homeostasis, Change in level of fibroblast growth factor 23 at 2 hours|Vitamin D, Biomarker of phosphate homeostasis, Change in level of vitamin D and vitamin D metabolites at 2 hours|klotho, Biomarker of phosphate homeostasis, Change in level of circulation kloth at 2 hours
|
| Sponsor/Collaborators: |
Sponsor: Dr. Rachel Holden
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
78
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER
|
| Start Date: |
2013-01
|
| Completion Date: |
2018-04-18
|
| Results First Posted: |
|
| Last Update Posted: |
2022-07-05
|
| Locations: |
Kingston General Hospital, Kingston, Ontario, K7L 3N6, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT02672293
|
